Detalhe da pesquisa
1.
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Hematol Oncol
; 41(3): 578-582, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043430
2.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Br J Haematol
; 192(3): 568-576, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33341940
3.
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Eur J Haematol
; 107(3): 318-323, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993536
4.
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Exp Hematol
; 111: 79-86, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417741
5.
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma.
Leukemia
; 35(12): 3534-3541, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326466